InFlectis BioScience: InFlectis BioScience Licenses Rights to a Potential New Class of Therapies for Demyelinating Diseases from The University of Chicago

(marketscreener.com) InFlectis BioScience has been granted exclusive patent rights from the University of Chicago to use a family of small molecules for the treatment of demyelinating diseases. The license covers the use of InFlectis BioSciences' lead compounds, IFB-088 and IFB-048, for the treatment of CMT and MS, two highly prevalent demyelinating diseases....https://www.marketscreener.com/news/latest/InFlectis-BioScience-Licenses-Rights-to-a-Potential-New-Class-of-Therapies-for-Demyelinating-Disease--35666969/?utm_medium=RSS&utm_content=20210622